MindMaze
$1Bpaper valuation
// OVERVIEW
MindMaze spent a decade convincing investors that virtual reality could rewire stroke patients' brains at commercial scale, raised $200 million to prove it, and discovered that hospitals prefer reimbursable treatments to aspirational neuroscience. The company that peaked at $1 billion in 2016 has spent eight years learning that digital therapeutics is the gap between what venture capital funds and what Medicare reimburses.
// HQ
Lausanne, Switzerland
// STATUS
PRIVATE
// FOUNDED
2012
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
ai
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
MindMaze builds VR-based neurological rehabilitation platforms that combine motion capture, brain-computer interfaces, and gamified therapy exercises for stroke and traumatic brain injury recovery. The underlying neuroscience — using immersive feedback to accelerate motor function recovery — is legitimate. The problem is that legitimate neuroscience and reimbursable medical device are describing different regulatory pathways with different timelines and neither pathway moves at venture scale.
// WOWLS ASSESSMENT
Digital therapeutics occupies the least profitable intersection in healthcare: slower than software, more regulated than pharmaceuticals, harder to reimburse than devices. MindMaze raised $200 million between 2012 and 2016, hit a $1 billion valuation at Series B, then went silent for seven years — no major funding rounds, no exit, no commercial traction metrics disclosed. Competitors like Hinge Health and Pear Therapeutics discovered the same reimbursement wall — Pear filed for bankruptcy in 2023 despite FDA clearance and $250 million raised. The VR stroke rehabilitation market MindMaze targeted in 2012 remains sub-$500 million globally in 2024 because physical therapy visits are reimbursed and VR headsets in hospital basements are not.
// WHY WOWLS HUNTS THIS
The gap between a 2016 peak valuation and 2024 absence of exit or follow-on funding is called a down round that has not been officially announced yet. Digital therapeutics companies have raised $9 billion collectively and produced exactly one profitable exit — the sector is a graveyard disguised as a waiting room.
// VALUATION NOTE
2016 Series B valuation of $1B is last publicly confirmed figure — no subsequent rounds disclosed, current valuation likely materially lower but not publicly marked down
VERDICT: PAPER TIGER — EIGHT YEARS FROM $1 BILLION VALUATION TO RADIO SILENCE IS NOT STEALTH MODE, IT IS A BUSINESS MODEL THAT ENCOUNTERED THE DIFFERENCE BETWEEN VENTURE ENTHUSIASM AND HOSPITAL PROCUREMENT COMMITTEES
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track MindMaze.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on MindMaze?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN